2021 Clinical Research Forum Top 10| Anti-Selig-8 Antibody for Eosinophilic Gastritis and Duodenitis скачать в хорошем качестве

2021 Clinical Research Forum Top 10| Anti-Selig-8 Antibody for Eosinophilic Gastritis and Duodenitis

Eosinophilic gastrointestinal disorders are an under-recognized cause of gastrointestinal illness. Increasing in incidence for reasons that are unclear, eosinophilic GI disorders have no FDA-approved therapies. Dr. Dellon and his colleagues performed a randomized controlled trial of lirentelimab, an anti-Siglec-8 antibody, in patients with eosinophilic gastritis and duodenitis. This study provides a potential therapeutic option for conditions afflicting thousands of patients, for whom other treatments were inadequate or too toxic for long-term use. It also provides proof-of-principle to advance our understanding of the pathogenesis of these conditions and their potential treatments. Given the significant challenges to treating EG and EoD, this study could significantly improve patient care.